SUMMARY

Heart failure (HF) is associated also with measures of systemic inflammation. There have been significant advances in the last decade in our understanding of how inflammation contributes to the pathogenesis and progression of HF.

Although some studies have validated the association between measures of inflammation and HF severity and prognosis, clinical trials of anti-inflammatory treatments were mostly unsuccessful. There is some discussion that we probably do not target the precise phenotypes within the syndrome of HF in these trials.

In this article we describe here mechanistic links between inflammation and HF, we discuss also traditional and novel inflammatory biomarkers and summarize the latest evidence from clinical trials of antiinflammatory therapies.
Key words: Heart failure, systemic inflammation, inflammatory mediators, treatment of inflammation in heart failure.
Lek Obz, 2022, 71 (3): 98-107

Ján MURÍN 1, Jozef BULAS 1, Martin WAWRUCH 2, Ľudovít GAŠPAR 1,3

1 I. interná klinika LF UK a UN Bratislava, prednostka doc. MUDr. S. Kiňová, PhD.
2 Ústav farmakológie a klinickej farmakológie LF UK Bratislava, prednosta prof. MUDr. M. Wawruch, PhD.
3 Fakulta zdravotníckych vied, UCM Trnava

Cite:
MURÍN J., BULAS J., WAWRUCH M., GAŠPAR Ľ.: Inflammation in heart failure. Lek Obz, 2022, 71 (3): 98-107